BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalathil D, John S, Nair AS. FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis. Front Oncol 2020;10:626836. [PMID: 33680951 DOI: 10.3389/fonc.2020.626836] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 li Y, wang M, Fan T, Wang Y, Chen L, Zhu C, Li Z, Mou L, Zhang Z, Chen L, Ali A, Dai J, Yang H. CD147 promotes cisplatin resistance in ovarian cancer by inhibiting FOXM1 degradation via PI3k/Akt-GSK3β pathway.. [DOI: 10.21203/rs.3.rs-2474599/v1] [Reference Citation Analysis]
2 Ding P, Liu L, Bin Y, Huang Y, Chen L, Wen L, Zhang R, Tong F, Dong X. T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma. J Clin Med 2022;11. [PMID: 36498802 DOI: 10.3390/jcm11237223] [Reference Citation Analysis]
3 Bao L, Festa F, Hirschler-Laszkiewicz I, Keefer K, Wang HG, Cheung JY, Miller BA. The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression. Sci Rep 2022;12:20544. [PMID: 36446940 DOI: 10.1038/s41598-022-25138-w] [Reference Citation Analysis]
4 Nakadai T, Yang L, Kumegawa K, Maruyama R. Estrogen receptor α K303R mutation reorganizes its binding to forkhead box protein A1 regions and induces chromatin opening. Mol Biol Rep 2022. [DOI: 10.1007/s11033-022-08089-3] [Reference Citation Analysis]
5 Wei G, Yang X, Lu H, Zhang L, Wei Y, Li H, Zhu M, Zhou X. Prognostic value and immunological role of FOXM1 in human solid tumors. Aging (Albany NY) 2022;14:9128-48. [PMID: 36435510 DOI: 10.18632/aging.204394] [Reference Citation Analysis]
6 Maier AD. Malignant meningioma. APMIS 2022;130:1-58. [DOI: 10.1111/apm.13276] [Reference Citation Analysis]
7 Shin M, Eun Choi Y, Yan L, Goh S, Choi Y. FOXM1 Inhibitor-Loaded Nanoliposomes for Enhanced Immunotherapy Against Cancer. Chemical Engineering Journal 2022. [DOI: 10.1016/j.cej.2022.140400] [Reference Citation Analysis]
8 Jafarzadeh A, Noori M, Sarrafzadeh S, Tamehri Zadeh SS, Nemati M, Chatrabnous N, Jafarzadeh S, Hamblin MR, Jafari Najaf Abadi MH, Mirzaei H. MicroRNA-383: A tumor suppressor miRNA in human cancer. Front Cell Dev Biol 2022;10:955486. [DOI: 10.3389/fcell.2022.955486] [Reference Citation Analysis]
9 Lee Y, Wu Z, Yang S, Schreiner SM, Gonzalez-Smith LD, Rhie SK. Characterizing and Targeting Genes Regulated by Transcription Factor MYBL2 in Lung Adenocarcinoma Cells. Cancers (Basel) 2022;14. [PMID: 36291764 DOI: 10.3390/cancers14204979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Koliopoulos MG, Muhammad R, Roumeliotis TI, Beuron F, Choudhary JS, Alfieri C. Structure of a nucleosome-bound MuvB transcription factor complex reveals DNA remodelling. Nat Commun 2022;13:5075. [PMID: 36038598 DOI: 10.1038/s41467-022-32798-9] [Reference Citation Analysis]
11 Qiu J, Tang Y, Liu L, Yu J, Chen Z, Chen H, Yuan R. FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma. Front Oncol 2022;12:815998. [DOI: 10.3389/fonc.2022.815998] [Reference Citation Analysis]
12 Madhi H, Lee JS, Choi YE, Li Y, Kim MH, Choi Y, Goh SH. FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation. Adv Sci (Weinh) 2022;:e2202702. [PMID: 35975458 DOI: 10.1002/advs.202202702] [Reference Citation Analysis]
13 Otálora-otálora BA, Osuna-garzón DA, Carvajal-parra MS, Cañas A, Montecino M, López-kleine L, Rojas A. Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis. Biology 2022;11:1082. [DOI: 10.3390/biology11071082] [Reference Citation Analysis]
14 Qiu J, Li M, Su C, Liang Y, Ou R, Chen X, Huang C, Zhang Y, Ye Y, Liao W, Zhang C. FOXS1 Promotes Tumor Progression by Upregulating CXCL8 in Colorectal Cancer. Front Oncol 2022;12:894043. [DOI: 10.3389/fonc.2022.894043] [Reference Citation Analysis]
15 Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. [DOI: 10.1038/s41388-022-02398-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Purrahman D, Avarvand AY, Paradowska-Gorycka A, Saki N, Karimpourian H, Jodat H, Mahmoudian-Sani MR. Association of human papillomavirus with breast cancer: a new perspective on an old debate. Future Oncol 2022. [PMID: 35695559 DOI: 10.2217/fon-2021-1158] [Reference Citation Analysis]
17 Smart E, Semina SE, Alejo LH, Kansara NS, Frasor J. Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors. Cancers (Basel) 2022;14:2848. [PMID: 35740514 DOI: 10.3390/cancers14122848] [Reference Citation Analysis]
18 Zhao X, Chen H, Qiu Y, Cui L. FAM64A promotes HNSCC tumorigenesis by mediating transcriptional autoregulation of FOXM1. Int J Oral Sci 2022;14:25. [PMID: 35538067 DOI: 10.1038/s41368-022-00174-4] [Reference Citation Analysis]
19 Liu S, Zhang Q, Liu W, Huang X. Research on the mechanisms of Shu Yu wan in the treatment of cervical cancer based on network pharmacology analyses and molecular docking technology. Nat Prod Res 2022;:1-5. [PMID: 35503243 DOI: 10.1080/14786419.2022.2071884] [Reference Citation Analysis]
20 Ouchi Y, Sahu SK, Izpisua Belmonte JC. FOXM1 delays senescence and extends lifespan. Nat Aging 2022;2:373-374. [DOI: 10.1038/s43587-022-00222-y] [Reference Citation Analysis]
21 Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 2022. [PMID: 35444283 DOI: 10.1038/s41586-022-04638-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Hirschler-Laszkiewicz I, Festa F, Huang S, Moldovan GL, Nicolae C, Dhoonmoon A, Bao L, Keefer K, Chen SJ, Wang HG, Cheung JY, Miller BA. The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1. Sci Rep 2022;12:6311. [PMID: 35428820 DOI: 10.1038/s41598-022-10385-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. J Exp Clin Cancer Res 2022;41:83. [PMID: 35241126 DOI: 10.1186/s13046-022-02295-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Tsoi H, You CP, Leung MH, Man EPS, Khoo US. Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. Cancers (Basel) 2022;14:1251. [PMID: 35267559 DOI: 10.3390/cancers14051251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sousa C, Silva-lima B, Videira M. Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers. Onco 2022;2:36-55. [DOI: 10.3390/onco2010004] [Reference Citation Analysis]
26 Ni L, Sun P, Fan X, Li Z, Ren H, Li J. Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma. Front Pharmacol 2021;12:775514. [PMID: 35173608 DOI: 10.3389/fphar.2021.775514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wu SQ, Huang SH, Lin QW, Tang YX, Huang L, Xu YG, Wang SP. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. Pharmacol Res 2021;175:106040. [PMID: 34954029 DOI: 10.1016/j.phrs.2021.106040] [Reference Citation Analysis]
28 Wang SP, Li Y, Huang SH, Wu SQ, Gao LL, Sun Q, Lin QW, Huang L, Meng LQ, Zou Y, Zhu QH, Xu YG. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. J Med Chem 2021;64:17413-35. [PMID: 34813314 DOI: 10.1021/acs.jmedchem.1c01535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wang SP, Wu SQ, Huang SH, Tang YX, Meng LQ, Liu F, Zhu QH, Xu YG. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. Cell Death Dis 2021;12:1138. [PMID: 34880209 DOI: 10.1038/s41419-021-04434-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Jeong JH, Ryu J, Lee HJ. In Vitro Inhibition of Piper nigrum and Piperine on Growth, Migration, and Invasion of PANC-1 Human Pancreatic Cancer Cells. Natural Product Communications 2021;16:1934578X2110576. [DOI: 10.1177/1934578x211057694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Zhang YL, Ma Y, Zeng YQ, Liu Y, He EP, Liu YT, Qiao FL, Yu R, Wang YS, Wu XY, Leng P. A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med 2021;9:1704. [PMID: 34988213 DOI: 10.21037/atm-21-5271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Gopalakrishnan S, Ismail A. Aromatic monophenols from cinnamon bark act as proteasome inhibitors by upregulating ER stress, suppressing FoxM1 expression, and inducing apoptosis in prostate cancer cells. Phytother Res 2021. [PMID: 34363252 DOI: 10.1002/ptr.7236] [Reference Citation Analysis]
33 Liu C, Barger CJ, Karpf AR. FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer. Cancers (Basel) 2021;13:3065. [PMID: 34205406 DOI: 10.3390/cancers13123065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
34 Barger CJ, Chee L, Albahrani M, Munoz-Trujillo C, Boghean L, Branick C, Odunsi K, Drapkin R, Zou L, Karpf AR. Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer. Elife 2021;10:e55070. [PMID: 33890574 DOI: 10.7554/eLife.55070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Gallo D, Young JT, Fourtounis J, Martino G, Álvarez-quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-desjardins C, de Rugy TG, Leclaire M, Liu B, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Gary Marshall C, Durocher D. CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition.. [DOI: 10.1101/2021.04.08.438361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Ibrahim R, Shash L, Elgohary S. FOXM1 and β-catenin in meningiomas: biomarkers for tumor proliferation and progression. Egypt J Pathol 2021;41:137. [DOI: 10.4103/egjp.egjp_44_21] [Reference Citation Analysis]